Evaluation of probiotics efficiency for the prevention of Clostridioides difficile infection in hospitalized patients: a systematic review and meta-analysis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Clostridioides difficile infection (CDI) poses a significant healthcare challenge, with the most frequent cause being antibiotic-associated diarrhea, affecting hospitalized individuals with substantial cost and mortality concerns. However, there is no information regarding probiotic efficiency for initial CDI treatment, and the modulation of microbiota by probiotics has been suggested as a potential preventive measure against CDI. Objective To evaluate the efficacy of probiotics in preventing CDI in hospitalized patients. Methods An exhaustive literature search was performed using PubMed to identify controlled/clinical trials investigating the use of probiotics for CDI prevention among hospitalized individuals based on PRISMA guidelines and the PICO framework. Relevant data were extracted from selected studies. Statistical meta-analysis (subgroup or sensitivity analyses) was performed using R Studio to calculate the pooled effect size, odds ratio (OR) with a 95% CI, p-value, and heterogeneity. The risk of bias was assessed using the Cochrane risk-of-bias (RoB) tool to determine publication bias and sensitivity of the included studies. Results Four studies with a significant number of participants were identified and included in the meta-analysis. The incidence of CDI was reduced in the probiotic group compared to the placebo group, with an overall OR of 0.99 (95% CI [0.56; 1.7]), increased heterogeneity, and a non-significant p-value, using a random effects model i…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931 · cited 1×
“Clostridium difficile infection (CDI) is the most common pathogen caus - ing healthcare-associated infections in the United States and is designated an ‘urgent threat’ by the Centers for Disease Control and Prevention [1 ].”
Clostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub3 · Cited by 741
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab549 · Cited by 674
The epidemiology of community-acquired Clostridium difficile infection: a population-based study
Khanna, S., Pardi, D. S., Aronson, S. L., Kammer, P. P., Orenstein, R., St Sauver, J. L., Harmsen, S. W., & Zinsmeister, A. R. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.398 · Cited by 622
Probiotics for the prevention of pediatric antibiotic-associated diarrhea
Goldenberg, J. Z., Lytvyn, L., Steurich, J., Parkin, P., Mahant, S., & Johnston, B. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004827.pub4 · Cited by 607
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566 · cited 1×
“Colonization resistance against C. difficile may be further improved by sustainably increasing microbiome diversity by recapitulating the complete colonic microbiota [12].”
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K.-F., Beardsley, J., Mertz, D., & Johnston, B. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub4 · Cited by 550
Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity
Wang, X., Zhang, P., & Zhang, X. (2021) · Molecules · doi:10.3390/molecules26196076 · Cited by 529 · cited 2×
“The use of probiotics as supplemental measures to support and regulate gut microbiota has gained wide - spread acceptance [7] and the administration of probiotics during antibiotic therapy may lower the risk of developing CDI [ 5, 19].”
Journal of Pediatric Gastroenterology and Nutrition: Quo Vadis?
Lebenthal, E. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318244d27e · Cited by 512
Probiotics for the prevention of pediatric antibiotic-associated diarrhea
Guo, Q., Goldenberg, J. Z., Humphrey, C., El Dib, R., & Johnston, B. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004827.pub5 · Cited by 275
Probiotics for the Prevention of Antibiotic‐Associated Diarrhea in Children
Szajewska, H., Canani, R. B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Shamir, R., Vandenplas, Y., van Goudoever, J. B., et al. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001081 · Cited by 268 · cited 1×
“However, the effectiveness of probiotics is mostly strain-specific, and it is important to determine the safety and effectiveness of each probiotic strain indepen - dently [18].”
Szajewska, H., & Kołodziej, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13404 · Cited by 223
Szajewska, H., & Kołodziej, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13344 · Cited by 217
Louie, T., Golan, Y., Khanna, S., Bobilev, D., Erpelding, N., Fratazzi, C., Carini, M., Menon, R., Ruisi, M., Norman, J. M., et al. (2023) · JAMA · doi:10.1001/jama.2023.4314 · Cited by 203
Clostridium difficile Infection
Sharma, S., Nakajima, K., & Shukla, P. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1506004 · Cited by 196
Ma, G. K., Brensinger, C. M., Wu, Q., & Lewis, J. D. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2733 · Cited by 175
Desai, K., Gupta, S. B., Dubberke, E. R., Prabhu, V. S., Browne, C., & Mast, T. C. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1610-3 · Cited by 158
Seekatz, A. M., Theriot, C. M., Molloy, C. T., Wozniak, K. L., Bergin, I. L., & Young, V. B. (2015) · Infection and Immunity · doi:10.1128/iai.00459-15 · Cited by 143
A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO)
Barker, A., Duster, M. N., Valentine, S., Hess, T., Archbald‐Pannone, L. R., Guerrant, R. L., & Safdar, N. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx254 · Cited by 114 · cited 1×
“…were assessed for eli - gibility, of which two research studies were not accessible; one was an RCT but focused on conducting thematic analy - sis instead of the statistical method [24 ], two were clinical protocols of the trials [25, 26 ], and five did not meet the inclusion criteria [21, 27–30 ].”
Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options
Goudarzi, M., Seyedjavadi, S. S., Goudarzi, H., Mehdizadeh Aghdam, E., & Nazeri, S. (2014) · Scientifica · doi:10.1155/2014/916826 · Cited by 109 · cited 1×
“Antibiotics can reduce the diversity and abundance of healthy bacteria, which, in turn, dimin - ishes colonization resistance and creates an environment for the growth, proliferation, pathogenesis, colonization, and toxin production of C. difficile [4–7].”
1016 – Probiotics for the Prevention of Pediatric Antibioticassociated Diarrhea
Guo, Q., Goldenberg, J. Z., Humphrey, C., Dib, R. E., & Johnston, B. C. (2019) · Gastroenterology · doi:10.1016/s0016-5085(19)37348-2 · Cited by 97
Colonization Resistance of the Gut Microbiota against Clostridium difficile
Pérez-Cobas, A., Moya, A., Gosalbes, M., & Latorre, A. (2015) · Antibiotics · doi:10.3390/antibiotics4030337 · Cited by 83 · cited 1×
“Low microbiome diversity and decreased colonization resistance to CDI are hallmarks of dysbiosis, which is caused by disturbance of the colonic microbiota following antibi - otic exposure [10–13].”
InfluentialKoradia, P., Kapadia, S. N., Trivedi, Y. N., Chanchu, G., & Harper, A. J. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1664287 · Cited by 82 · cited 1×
“…were assessed for eli - gibility, of which two research studies were not accessible; one was an RCT but focused on conducting thematic analy - sis instead of the statistical method [24 ], two were clinical protocols of the trials [25, 26 ], and five did not meet the inclusion criteria [21, 27–30 ].”
Alberda, C., Marcushamer, S., Hewer, T., Journault, N., & Kutsogiannis, D. J. (2018) · Nutrients · doi:10.3390/nu10050539 · Cited by 63 · cited 6×
“Almost all studies were randomized controlled trials (RCTs), except for two [ 33, 34 ], which were case-controlled and controlled prospective intervention study designs.”
InfluentialKołodziej, M., & Szajewska, H. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.08.017 · Cited by 59
Rajkumar, C., Wilks, M., Islam, J., Ali, K., Raftery, J. P., Davies, K. A., Timeyin, J., Cheek, E., Cohen, J., Wright, J. E., et al. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.01.018 · Cited by 41
Carstensen, J. W., Chehri, M., Schønning, K., Rasmussen, S. C., Anhøj, J., Godtfredsen, N. S., Andersen, C. Ø., & Petersen, A. M. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3267-x · Cited by 29 · cited 1×
“When only non-RCTs (Alberda et al. 2018; Carstensen et al. 2018) were analyzed, the pooled odds ratio was 0.60 [0.43; 0.84], which indicates a statistically signifi - cant reduction in CDI incidence as compared to the placebo group while favoring the probiotic group.”
InfluentialAllegretti, J. R., Kelly, C. R., Louie, T., Fischer, M., Hota, S. S., Misra, B. K., van Hise, N., Yen, E. F., Bullock, J., Silverman, M., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.030 · Cited by 28 · cited 1×
“Meanwhile, when RCTs (Rajkumar et al. 2019; Allegretti et al. 2025) Fig.”
Kołodziej, M., & Szajewska, H. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013928 · Cited by 23
Clostridium difficile control measures: current and future methods for prevention
Mejía-Chew, C., & Dubberke, E. R. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1429911 · Cited by 17
Probiotics and antibiotic-associated diarrhoea
Kalil, A. C., & Schooneveld, T. C. V. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62734-8 · Cited by 15 · cited 2×
“Evidence suggests that antibiotic medication causes dysbiosis in the commensal gut microbiota that can be reduced by administering pro-biotics to avoid antibiotic-associated diarrhea (AAD) [ 15].”
Alsaggaf, R., O’Hara, L. M., Stafford, K. A., Leekha, S., & Harris, A. D. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.296 · Cited by 14
Owen-Jones, E., Lowe, R., Lown, M. T., Gillespie, D., Addison, K., Bayer, A. J., Calder, P. C., Davies, J. H., Davoudianfar, M., Downs, J. L., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027513 · Cited by 12
Leal, J. R., Shen, Y., Faris, P., Dalton, B., Sabuda, D. M., Ocampo, W., Bresee, L. C., Chow, B., Fletcher, J. R., Henderson, E., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.169 · Cited by 9
Bresee, L. C., Lamont, N. C., Ocampo, W., Holroyd-Leduc, J. M., Sabuda, D. M., Leal, J. R., Dalton, B., Kaufman, J., Missaghi, B., Kim, J., et al. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-10350-9 · Cited by 4
Cited by
Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies
Niu, C., Wang, J., Lu, X., & Yu, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1787284 · Cited by 7
Chen, W., Pan, X., Ji, J., Wu, Z., & Lin, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1699223 · Cited by 3
Probiotics unveiled: bridging general health benefits to the era of precision medicine
Ullah, M., Rizwan, M., Waheed, M. I., Alam, M. S., Jan, S. U., Raza, A., Shahid, M. F., Andoh, V., & Chen, Y. (2026) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-026-05143-1
Douglass, M. V., Melton, L. R., Calcutt, M. W., McNeely, T. P., Price, S. L., Munneke, M. J., & Skaar, E. P. (2026) · Science Signaling · doi:10.1126/scisignal.aef8846
Metadata
- Authors
- Almutawif, Y. A., Najim, M. A., & Khan, N. U.
- Affiliations
- Taibah University (SA)
- The University of Agriculture, Peshawar (PK)
- Corresponding author
- Khan, Najeeb Ullah
- Venue
- Infection
- Published
- 2025-06-10
- Volume
- 53
- Issue
- 6
- Pages
- 2455-2466
- ISSN
- 0300-8126 (ISSN-L)
- 1439-0973
- OpenAlex
- W4411188151
- Cited by
- 4
- References
- 39
- Citations by year
- 2026: 4
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Infection (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, Clostridium difficile infection, infection control, hospitalized patients, antibiotic-associated diarrhea, gut microbiota modulation, risk of bias
- MeSH terms
- Clostridium Infections, Cross Infection, Hospitalization, Humans, Clostridioides difficile, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.